TMPRSS2 and prostate adenocarcinoma: TMPRSS2-ERG is the most common fusion in prostate adenocarcinomas (50%) and in precursor high-grade prostatic intraepithelial neoplasia (approximately 20%) [26, 28], and promotes metastasis to bone [29].